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Abstract 
Context: Antipituitary antibodies (APA) but not antihypothalamus antibodies (AHA) are usually searched for in 
autoimmune hypopituitarism. 
Objective: Our objective was to search for AHA and characterize their hypothalamic target in patients with autoimmune 
hypopituitarism to clarify, on the basis of the cells stained by these antibodies, the occurrence of autoimmune 
subclinical/clinical central diabetes insipidus (CDI) and/or possible joint hypothalamic contribution to their 
hypopituitarism. 
Design:  We conducted a cross-sectional cohort    study. 
Patients: Ninety-five APA-positive patients with autoimmune hypopituitarism, 60 without (group 
1) and 35 with (group 2) lymphocytic hypophysitis, were studied in comparison with 20 patients with postsurgical 
hypopituitarism and 50 normal subjects. 
Main Outcome Measures: AHA by immunofluorescence and posterior pituitary function were evaluated; then AHA-
positive sera were retested by double immunofluorescence to identify  the hypothalamic cells targeted by  AHA. 
Results: AHA were detected at high titer in 12 patients in group 1 and in eight patients in group 2. They immunostained 
arginine vasopressin (AVP)-secreting cells in nine of 12 in group 1 and in four of eight in group 2. All AVP cell antibody-
positive patients presented with subclinical/clinical CDI; in contrast, four patients with GH/ACTH deficiency but with 
APA staining only GH-secreting cells showed AHA targeting CRH- secreting cells. 
Conclusion: The occurrence of CDI in patients with lymphocytic hypophysitis seems due to an auto- immune 
hypothalamic involvement rather than an expansion of the pituitary inflammatory process. To search for AVP antibody in 
these patients may help to identify those of them prone to develop an autoimmune CDI. The detection of AHA targeting 
CRH-secreting cells in some patients with GH/ACTH deficiency but with APA targeting only GH-secreting cells 
indicates that an autoimmune aggression to hypothalamus is jointly responsible for their hypopituitarism. 
Introduction 
he pituitary autoimmunity is a complex spectrum of de- fined conditions such as histologically proven or sus- pected 
lymphocytic hypophysitis (LYH) causing autoim- mune hypopituitarism,  associated  in the majority  of cases 
with the presence of antipituitary antibodies (APA) (1–5). 
It has been also shown that central diabetes insipidus (CDI) may occur in some patients with proven/suspected LYH as a 
result of possible expansion of an inflammatory process from anterior to posterior lobe, with swelling of the pars tuberalis 
of the adenohypophysis covering the infundibulum laterally and consequent inhibition of the axonal transport of 
antidiuretic hormone (4, 6,   7). 
However, many years ago, Scherbaum et al. (8) showed that CDI could be caused by an autoimmune process to 
magnocellular hypothalamic neurons secreting arginine vasopressin (AVP); in fact, antibodies against AVP-secret- ing 
cells (AVPcAb) were detected in sera of many patients with idiopathic subclinical/clinical CDI  (9 –11). 
Furthermore, Scherbaum (12) showed that sera of some patients with idiopathic CDI and of some patients with 
autoimmune polyendocrine syndrome without CDI im- munostained unidentified small hypothalamic non-AVP- secreting 
cells, suggesting that they could be hypothalamic releasing-hormone-secreting   cells. 
Many years later, Tanriverdi and colleagues (13, 14) showed that not only APA but also antihypothalamus an- tibodies 
(AHA) can be present in patients with hypopitu- itarism secondary to Sheehan’s syndrome and in boxers with late 
hypopituitarism secondary to cranial trauma, suggesting that a hypothalamic autoimmunity could have a role in the 
pathogenesis of  hypopituitarism. 
However, the role of hypothalamus autoimmunity in patients with isolated or multiple pituitary hormone de- ficiencies 
with or without LYH and with or without CDI has been so far not investigated. 
  
 
The aim of this study was to search for AHA in patients with autoimmune hypopituitarism, previously found pos- itive for 
APA, evaluating in those who were AHA positive, by a four-layer double immunofluorescence, whether the cells targeted 
by these antibodies were AVP-secreting cells or other hypothalamic cells, such as, in particular, CRH- secreting cells. 
This was to clarify whether a concomitant autoimmune aggression to the hypothalamus, rather than an expansion of the 
inflammatory pituitary process to pos- terior pituitary and infundibulum, may be responsible in these patients for the 
occurrence of CDI and/or may con- tribute to their hypopituitarism. 
 
Patients and Methods 
Patients 
From 2004 –2011 in the Immunoendocrinology Laboratory of the Second University of Naples, we performed an APA 
screening by indirect immunofluorescence in sera of a large cohort of patients with idiopathic hypopituitarism sent to our 
laboratory by the Ital- ian autoimmune hypophysitis Network Study Group and other several International 
Endocrinological Units. Ninety-five of these patients, found positive for APA at high titers and presenting with 
autoimmune hypopituitarism and single or multiple pituitary hor- mone deficiencies, were recruited and grouped as 
follows: sixty (14 males, 46 females; mean age 31.5 yr, age range 26 –37 yr) without histological or magnetic resonance 
imaging (MRI) findings of LYH (group 1), and 35 (eight males, 27 females; mean age 32 yr, age range 25–38 yr) with 
biopsy-proven or MRI-suspected LYH (group 
2) on the basis of the criteria previously reported in the literature (7, 15–21). Immunological and clinical findings of 
patients of both groups are illustrated in Table 1. 
The diagnosis of hypopituitarism had been made following the criteria previously described (22, 23). In particular, ACTH 
deficiency (ACTH-D), in the presence of normal or low basal serum levels of ACTH, had been suspected when the 0800-
h cortisol level was below 193 nmol/liter and confirmed by an impaired cortisol response to the 1-µg tetracosactide test 
(<497 nmol/liter). GH-D had been diagnosed in presence of low-nor- mal basal IGF-I and impaired GH response to the 
GHRH plus arginine test (GH peak <9.0 µg/liter). Gonadotropin deficiency had been diagnosed in males when basal 
testosterone levels were below the normal range (total testosterone <9 nmol/liter) in the presence of normal or low 
gonadotropin levels. A similar diag- nosis in females had been supported by serum estradiol levels lower than 40 
pmol/liter associated with inappropriately low serum gonadotropin concentrations. TSH-Dhad been diagnosed in patients 
with inappropriately low serum TSH levels in the presence of subnormal serum free T4 and free T3 concentrations. 
Posterior pituitary function was studied in all patients. 
AHA were searched for in all patients. Moreover, the pres- ence of antibodies to AVP-secreting cells and to CRH-
secreting cells in all those positive for AHA was also investigated by four- layer double immunofluorescence. As 
controls, AHA were searched for in 20 patients with hypopituitarism secondary to hypophysectomy and in 50 sex- and 
age-matched healthy sub- jects. The 20 patients with postsurgical hypopituitarism and the 50 healthy subjects were the 
same ones that had been studied and published in a previous paper (24). All patients and controls gave their informed 




AHA were detected by a simple indirect immunofluorescence method on cryostat sections of young baboon 
hypothalamus supplied by Biomedis srl (Porto San Giorgio, Italy), as previously described (9, 13, 14). In particular, 
unfixed cryostat sections of young normal baboon hypothalamus were initially incubated with the sera. Then, serum 
samples were subsequently tested with fluorescein isothiocyanate-conjugated goat antihuman Ig. We considered AHA 
positive at middle titer when ranging from 1:16 to 1:32 and at high titer when over 1:32. However, taking into account the 
low specificity of the immunofluorescence method, we considered for our analysis only the patients positive for  AHA  at  
high titer. 
Sera of all patients positive for AHA were retested by a four- layer double immunofluorescence, as previously reported 
(9, 10, 
24) to verify whether hypothalamic cells targeted by these anti- bodies were AVP-secreting cells or other hypothalamic 
cells, in particular CRH-secreting cells. To this purpose, sera positive for AHA were retested in a second step on the same 
hypothalamic cryostat section, with specific rabbit anti-AVP sera (supplied by Histo-Line Laboratories srl, Milan, Italy) 
or anti-CRH sera (Bio- genesis Ltd., Poole, UK, supplied by Histo-Line), respectively, followed by rhodamine antirabbit  
Ig. 
The different colors of the anti-Ig conjugates against the hu- man serum and against the animal serum, respectively, green 
(fluorescein isothiocyanate) and red (rhodamine), allowed direct assessment of whether the patient’s serum and the 
animal’s se- rum stained the same (AVP- or CRH-secreting cells, respectively) or different hypothalamic cells. 
Posterior pituitary function 
The diagnosis of CDI was suspected on the basis of polyuria and polydipsia and urinary and plasma osmolality and con- 
firmed by a dehydration plus desmopressin administration test, as previously described (9, 10, 25). An increase of urinary 
os- molality from 10 –50% or more than 50% after desmopressin injection was taken to indicate partial or complete CDI. 
More- over, in all patients, the diagnosis of complete or partial CDI was confirmed by the evaluation of plasma AVP 
levels after the de- hydration test; an absent or subnormal AVP response to the water-deprivation test were confirmatory 
of complete or partial CDI,  respectively  (9, 26). 
Statistical analysis 
Statistical analysis was performed by using the SPSS version 13.0 program. Data are expressed as mean ± SD, unless 
otherwise specified. Nonparametric tests were used because of the non- Gaussian distribution of the data. Differences 
between the fre- quencies were evaluated by x2 test. 
The differences between the groups were compared by un- paired t test, and nonnormally distributed data were compared 
by Mann-Whitney U test. In addition, Pearson or Spearman’s correlation analysis was performed to determine whether 
signif- icant correlations existed between chosen variables. P < 0.05 was considered statistically significant. 
 
Results 
On the basis of characterization of types of pituitary hor- mone-secreting cells targeted by APA, previously per- formed 
by four-layer double immunofluorescence, 53 pa- tients in group 1 and 29 in group 2 had shown correlation between the 
kind of pituitary hormone deficiency and the type of pituitary hormone-secreting cells targeted by APA. In particular, in 
43 patients in group 1 and 18 in group 2 with isolated  GH-D,  ACTH-D,  LH-/FSH-D  or  TSH-D, APA had been seen 
targeting selectively pituitary GH-, ACTH-, LH-/FSH-, or TSH-secreting cells, respectively. Instead, among the 34 
patients with combined pituitary hormone deficiencies, seven in group 1 and six in group 2 had shown APA targeting 
only one type of pituitary  hormone-secreting cell (Table 1). 
AHA were present in 34 of 95 patients with autoim- mune hypopituitarism (37.8%) and in particular in 20 of 60 in group 
1 (33.3%) and 14 of 35 in group 2 (40%); these antibodies were present at high titer (from 1:64 to 1:256) in 12 in group 1 
and in eight in group 2 (Fig. 1) although at middle titer (<1:32) in eight patients in group 1 and in six in group 2. AHA 
were absent in all patients with hypopituitarism secondary to hypophysectomy and in normal subjects. 
CDI occurred in 13 of 95 patients with autoimmune hypopituitarism (13.7%), of whom nine (five in clinical and four in 
subclinical phase) in group 1 (15%) and four (all in clinical phase) in group 2 (11.4%); no significant difference of 
frequency of CDI was observed between group 1 and group  2. 
All 13 patients with CDI were positive for AHA, whereas none of the AHA-negative patients showed CDI; thus, a higher 
significant frequency of CDI was evidenced in AHA-positive patients with respect to those negative for these antibodies 
(P < 0.001). No significant difference of sex, age, type of hypopituitarism, association with other autoimmune disease, 
APA titer, or morphological findings on MRI were observed between AHA-positive and AHA- negative patients. 
In all 13 patients with CDI, AHA were present at high titer and showed selectively or prevalently immunostain- ing of 
magnocellular hypothalamic cells (type 1 pattern, Fig.  2A). 
In the remaining seven AHA-posi- tive patients at high titer but without CDI (three in group 1 and four in group 2), these 
antibodies immunostained se- lectively small hypothalamic cells (type 2 pattern, Fig.  2B). 
When considering the previously performed characterization of types of pituitary hormone-secreting cells tar- geted by 
APA, some patients with CDI (five in group 1 and two in group 2) had shown specific correspondence be- tween the kind 
of pituitary hormone de- ficiency and the type of pituitary hor- mone-secreting cells stained by APA. 
In other patients with CDI (four in group 1 and two in group 2) and in all patients without CDI and with com- bined 
pituitary hormone deficiencies, APA was shown targeting only one type of pituitary hormone-secreting cells. 
The results of double immunofluo- rescence in sera of AHA-positive  pa- tients showed that in all CDI patients with type 
1 pattern the magnocellular hypothalamic cells stained by AHA were AVP-secreting cells (Fig. 2C). Moreover, in four 
pa- tients (two in group 1 and two in group 2) presenting with GH-D associated with ACTH-D but with APA targeting 
only the somatotrophs and with type 2 pattern of AHA, the double immunofluorescence showed that AHA stained mainly 
small hypothalamic cells, identified as CRH-secreting  cells  (Fig. 2D). 
Instead, in the remaining two AHA-positive patients with ACTH-D, one in group 1 associated with TSH-D and one in 
group 2 associated with FSH-/LH-D, in whom APA had stained only ACTH-secreting cells, the double immu- 
nofluorescence showed that AHA were directed against unknown small hypothalamic cells different from CRH- secreting 
cells. Moreover, in none of AHA-positive pa- tients without ACTH-D did AHA stain CRH-secreting cells. The 







The first result of our study is the finding, for the first time, of AHA in some patients with isolated or combined  pitu- 
itary deficiencies with or without proven/suspected LYH and  with  or  without CDI. 
Another point emerging from our results is the occur- rence of CDI exclusively in AHA-positive patients. Inter- estingly, 
CDI occurred not only in those with expansion of pituitary gland to suprasellar region but also mostly in those without 
significant increased volume of pituitary gland on MRI. 
In particular, our study evidenced that in all CDI patients with autoimmune hypopituitarism, AHA were present at high 
titer (>1:64) and were directed prevalently to magno- cellular hypothalamic cells, identified as AVP-secreting cells by 
double immunofluorescence. 
In a previous study, performed in patients with CDI with or without pituitary stalk thickening on MRI, we showed in the 
affected patients the presence of AVPcAb at high titer, independently from the presence of pituitary stalk thickening (27). 
The occurrence of CDI in patients with proven/sus- pected LYH has been usually attributed either to direct immune 
destruction or to compression of the posterior lobe or the infundibulum (4, 7, 8, 16, 17); however, studies regarding the 
presence of subclinical/clinical CDI in pa- tients with autoimmune hypopituitarism without definite or suspected findings 
of LYH are   lacking. 
On the basis of the results of the present study, we conclude that the occurrence of CDI in patients  with proven/suspected 
LYH can be often caused by a con- comitant autoimmune process involving hypothalamic AVP-secreting cells, even if it 
sometimes may be also associated with the expansion of inflammatory pro- cesses to the posterior lobe and by 
compression of the infundibulum. Thus, many of our APA-positive patients, found even positive for AHA identified as 
AVPcAb, may be considered as having an autoimmune CDI, associated with autoimmune pituitary dysfunction (28), 
despite apparently normal pituitary characteristics on   MRI. 
This also suggests that a simultaneous occurrence of subclinical/clinical autoimmune CDI in patients with au- toimmune 
hypophysitis may be more frequent than has been so far known and should lead to a search for AVPcAb in these patients 
to identify those of them prone to develop an autoimmune CDI. However, the possibility of inter- rupting the progression 
to a clinically overt disease in these patients is still under discussion. To tell the truth, in some other autoimmune 
endocrine diseases (29 –31), a treat- ment with the hormone of the gland aggressed by the im- mune process in an early 
stage, when the gland is not yet completely destroyed, seems to be able to interrupt the autoimmune cascade, thus 
allowing in some cases the re- covery of its function. However, the poor data appeared in the literature regarding an early 
therapy in patients with autoimmune CDI (10, 29, 32) do not allow us to draw decisive conclusions about this, because 
only one   paper was based on a longitudinal study of a small cohort of patients with subclinical autoimmune CDI (10) 
and with one being a case report (32). Thus, additional longitudinal studies on a more numerous cohort of patients with 
po- tential/subclinical CDI associated with autoimmune hy- popituitarism are needed to clarify these aspects. 
Another message emerging from our study is that in many AHA-positive patients with autoimmune hypopitu- itarism, 
associated or not with CDI, these antibodies im- munostained prevalently small hypothalamic non-AVP- secreting cells. 
Interestingly, the previously performed characterization of APA by double immunofluorescence in these patients had 
shown that these antibodies targeted only one type of pituitary hormone-secreting cell despite the occurrence of combined 
pituitary deficiencies. 
In a recent study performed in patients with idio- pathic ACTH deficiency, we detected in some of them APA targeting 
selectively pituitary ACTH-secreting cells and in others AHA targeting small hypothalamic cells that resulted, by double 
immunofluorescence, mainly CRH-secreting cells, suggesting an interesting possibility to differentiate secondary from 
tertiary vari- ants of autoimmune hypoadrenalism  (24). 
In the present study, we found that in some AHA-positive patients with GH-D associated with ACTH-D, previously 
found positive for APA targeting only somatotrophs but not adrenocorticotrophs, AHA immunostained prevalently small 
hypothalamic cells, identified by double immunofluo- rescence as CRH-secreting cells. These results indicate in these 
patients a possible association of GH-D, caused by an autoimmune aggression to pituitary GH-secreting cells, with a 
tertiary form of hypoadrenalism caused by autoimmune aggression to hypothalamic CRH-secreting cells. With this in 
mind, we can suppose that, in patients with other combined pituitary hormone deficiencies, including LH/FSH-D or TSH-
D and lack of correspondence with the respective pi- tuitary cells targeted by APA, the occurrence of their hypop- 
ituitarism could be the result of an autoimmune aggression to the corresponding releasing hormone-secreting cells. How- 
ever, the lack of studies using the four-layer double immu- nofluorescence for the characterization of other types of hy- 
pothalamic cells targeted by AHA (which are in progress) suggests caution against a generalization of our assumption. In 
conclusion, our results, taken together, indicate that the occurrence of CDI in subclinical/clinical forms in our patients 
with LYH seems to be more frequent than that so far known. The finding of AHA immunostaining AVP- secreting cells 
in these patients suggests that an autoim- mune process involving the hypothalamus, rather than an expansion of the 
pituitary inflammatory process, may be responsible for their CDI. Thus, to search for AVPcAb in these patients may be a 
useful tool to identify those of them 
  
 
who are prone to develop a clinically overt disease. Finally, the detection of AHA targeting small hypothalamic cells 
identified as CRH-secreting cells in some patients with GH- ACTH-D but with APA staining only GH-secreting cells in- 
dicates that not only pituitary but also hypothalamic auto- immunity may contribute to their anterior pituitary dysfunction. 
Thus, these patients may be considered as fall- ing into some types of autoimmune polyendocrine syn- drome, when their 
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 TABLE 1. Characteristics of the 95 patients with autoimmune hypopituitarism positive for 
APA at high titer (1:64 –1:256) 
Isolated pituitary 
hormone deficiency TPC-APA 
Combined pituitary 
hormone deficiencies TPC-APA 
 
   
 
APA-positive patients Type n GH LH/FSH TSH ACTH Type n GH LH/FSH TSH ACTH 
Group 1 (n = 60)  
Sex (M/F = 14/46) GH-D 19 19 0 0 0 GH-/ACTH-D 5 5 0 0 3 
Mean age = 31.5 yr LH/FSH-D 10 0 10 0 0 GH-/LH-FSH-D 4 4 2 0 0 
Age range = 26 –37 yr ACTH-D 14 0 0 0 14 GH-/TSH-D 2 2 0 2 0 
Other autoimmune diseases (n = 39)       LH-FSH-/ACTH-D 3 0 3 0 3 
       LH-FSH/TSH-D 1 0 1 0 0 
       ACTH-D/TSH-D 1 0 0 0 1 
       TSH-LH-FSH-D 1 0 0 1 0 
Group 2 (n = 35)             
Sex (M/F = 8/27) GH-D 7 7 0 0 0 GH-/ACTH-D 5 5 0 0 3 
Mean age = 32 yr LH/FSH-D 5 0 5 0 0 GH-/LH-FSH-D 4 4 2 0 0 
Age range = 25–38 yr ACTH-D 6 0 0 0 6 LH-FSH-/ACTH-D 6 0 5 0 6 
Other autoimmune diseases (n = 19)       LH-FSH-/TSH-D 2 0 2 1 0 
Of the 95 patients, 60 were without histological/MRI findings of LYH (group1) and 35 with biopsy proven/MRI suspected 







TABLE  2.  Characteristics of the 20 patients with autoimmune hypopituitarism 





















AVP-  secreting cells 




Group1 (n = 12)          
1 GH-D  GH M 27 1:256 Present Absent Complete CDI
a
 
2  GH-/ACTH-D GH F 29 1:128 Absent Present  (CRH cells) Normal 
3  GH-/FSH-LH-D GH M 31 1:64 Present Present  (unknown cells) Partial CDI
b
 
4 GH-D  GH F 29 1:256 Present Absent Complete CDI
a
 
5  ACTH-/TSH-D ACTH F 33 1:64 Present Present  (unknown cells) Partial CDI
b
 
6  GH-/FSH-LH-D GH/FSH-LH F 31 1:64 Present Absent Complete CDI
a
 
7  GH-/ACTH-D GH M 37 1:256 Absent Present  (CRH cells) Normal 
8  GH-/FSH-LH-D GH/FSH-LH F 30 1:128 Present Absent Complete CDI
a
 
9  GH-/FSH-LH-D GH F 34 1:64 Present Present  (unknown cells) Partial CDI
b
 
10  FSH-LH-/TSH-D FSH-LH F 28 1:64 Present Present  (unknown cells) Partial CDI
b
 
11  FSH-LH-/TSH-D TSH F 30 1:256 Absent Present  (unknown cells) Normal 
12 GH-D  GH F 28 1:128 Present Absent Complete CDI
a
 
Group 2 (n = 8)          
1 GH-/FSH-LH-D GH/FSH-LH F 30 1:256 Present Absent Complete CDIa 
2 FSH-LH-/ACTHD ACTH M 29 1:128 Absent Present  (unknown cells) Normal 
3 GH-/FSH-LH-D GH/FSH-LH F 28 1:128 Present Present  (unknown cells) Complete CDIa 
4 FSH-LH-/TSH-D FSH-LH/TSH M 32 1:128 Present Present  (unknown cells) Complete CDIa 
5 GH-/ACTH-D GH F 32 1:64 Absent Present  (CRH cells) Normal 
6 FSH-LH-/TSH-D FSH-LH F 33 1:64 Absent Present  (unknown cells) Normal 
7 GH-/FSH-LH-D GH/FSH-LH F 31 1:256 Present Absent Complete CDIa 
8 GH-/ACTH-D GH F 28 1:64 Absent Present  (CRH cells) Normal 
Of the 20 patients, 12 were without histological/MRI findings of LYH (group 1) and eight with biopsy-proven/MRI-
suspected lymphocytic hypophysitis (group 2). CPHD, Combined pituitary hormone deficiencies; F, female; IPHD, 
isolated pituitary hormone deficiency; M, male; TPC-APA, type of pituitary cells targeted by APA. 
a As diagnosed on the basis of basal urinary osmolarity ranging from 215–240 mOsm/kg and plasma osmolarity from 293–298 
mOsm/kg and urine osmolarity after dehydration from 130 –160 mOsm/kg and after ADH administration from 640 –760 
mOsm/kg. 
b As diagnosed on the basis of basal urinary osmolarity ranging from 357–380 mOsm/kg and plasma osmolarity from 283–286 








FIG. 1. Detection of AHA in 95 patients with autoimmune hypopituitarism, 60 without histological/MRI findings of LYH (group 1) and 35 
with proven/suspected LYH (group 2) positive for APA at high titer (1:64 –1:256), in 20 patients with hypopituitarism after 









FIG. 2. Immunofluorescence pattern in cryostat sections of young baboon hypothalamus tested against serum of one patient with CDI (A 
and C) and serum of one patient with ACTH- D (B and D) showing evidence of AHA immunostaining in the patient with CDI selectively of 
magnocellular hypothalamic cells (type 1 pattern, A), identified as AVP-secreting cells by four- layer immunofluorescence (C), and in the 
patient with ACTH-D selectively of small hypothalamic cells (type 2 pattern, B), identified as CRH-secreting cells by four-layer 
immunofluorescence (D). 
